Medicine composition for treating hepatic disease and use thereof
A composition and drug technology, applied in the field of pharmaceutical compositions for the treatment of liver diseases, can solve the problems of toxic side effects, inhibitory effects, and lack of specificity of chemical drugs, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0104] Example 1 Extraction of the compound Wedelia lactone from Eclipta alba
[0105] (1) Soaking and filtering
[0106] Eclipta prostrata 300kg, completely immersed in 0.75 tons of ethanol (concentration 95%) → soaked overnight (10 hours) → coarse filtration to remove the whole plant residue (retention) → net filtration (suction filtration) or high-speed centrifugation (10000rpm, 10 minutes) to remove dust and fine residue → green clear filtrate.
[0108] Distillation and recovery of ethanol, the temperature does not exceed 60 ℃ → back distillation for 2 hours each time, remove the extract in the reactor to the collection bucket (the extract is dark green, slightly viscous) → repeat the above steps until all the ethanol is recovered .
[0109] (3) Secondary soaking and back distillation
[0110] Recover 0.75 tons of ethanol, re-soak the whole grass residue → soak overnight, and the requirements for coarse filtration, net filtration and distillation recov...
Embodiment 2
[0122] Example 2 Wedelia lactone enhances the activity of IFN-γ cytokine
[0123] JAK / STAT signal transduction system is a signal transduction pathway widely used by IFN and type I cytokines. These cytokines first activate JAK kinase, and then phosphorylate and activate STAT protein. The activated STAT protein undergoes nuclear translocation and regulates gene expression.
[0124] Experimental Materials:
[0125] 1) Cell line: stably transfected with STAT 1 -HepG of luciferase reporter gene plasmid 2 cell
[0126] 2) Drugs to be tested: AP-1, IFN-γ (Sigma, Cat.NO.TO157)
[0127] 3) Luciferase detection kit (Promega, Cat.NO.E4550)
[0128] experimental method:
[0129] 1) Add HepG in good growth condition 2 The cells are trypsinized, resuspend the cells in DMEM medium and adjust the cell concentration to 1×10 6 Cells / ml, inoculate 1ml of cell suspension in 96-well plate at 37℃, 5% CO 2 Cultivate overnight in an incubator until the cells are completely attached;
[0130] 2) When the cells g...
Embodiment 3A
[0142] Example 3 The protective effect of AP-1 combined with IFN-α on ConA-induced immune liver injury in mice
[0143] In 1992, Tiegs and others successfully used ConA (ConA) to induce specific liver damage in mice. In recent years, it has gradually developed into the main experimental model for studying immune cell-mediated liver damage.
[0144] Concanavalin (Concanavalin, ConA is a plant lectin, has a mitogenic effect, as a mitogen stimulates T lymphocytes to express a variety of cytokines TNF-α, IFN-γ, IL-2 mediate liver damage, ConA induces T lymphocytes The pathology of dependent liver injury is similar to human autoimmune liver disease, acute and chronic viral hepatitis, and can be alleviated by immunosuppressive agents.
[0145] Eight hours after the administration of ConA, plasma ALT, AST, LDH were significantly increased, a large number of T lymphocytes infiltrated in the liver, and part of the portal area lymphocyte infiltration showed "cuffing" changes, a large number of...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More